XII. 1. Chronic Diseases (Diabetes, Obesity, etc.)

Type 2 diabetes, obesity, and metabolic syndrome reshape the gut ecosystem, while the microbiota feeds back on insulin sensitivity and inflammation.

How Metabolic Conditions Reshape Your Gut Microbiota

Chronic metabolic conditions such as type 2 diabetes, obesity, and metabolic syndrome change the internal environment in which gut microbes live [39] [144].

The bidirectional relationship between gut microbiota^[G] and metabolic disease was established most dramatically by a series of fecal microbiota transplant experiments conducted between 2006 and 2013. Ridaura and colleagues (Washington University, 2013, Science) transplanted gut microbiota from obese and lean human twins into germ-free^[G] mice. Mice receiving obese donor microbiota gained significantly more fat mass than those receiving lean donor microbiota, despite consuming the same diet under identical conditions. The phenotype was transferable, demonstrating that the obese-associated microbiota could drive metabolic dysfunction independently of host genetics or dietary intake. [149] The earlier work by Cani and colleagues (2007, Diabetes) established the endotoxemia hypothesis: high-fat diet feeding in mice increased intestinal permeability^[G], elevating circulating bacterial LPS by 2- to 3-fold. This "metabolic endotoxemia" was sufficient to produce obesity, insulin resistance, and adipose tissue inflammation even in the absence of excess caloric intake, mediated through TLR4-dependent innate immune activation. [144] The mechanistic picture that emerged from these and subsequent studies identified several microbiota-dependent pathways contributing to metabolic disease: reduced butyrate (a short-chain fatty acid that is the primary energy source for colonocytes) (a short-chain fatty acid^[G] that nourishes colon cells and reduces inflammation) production impairing gut barrier integrity, altered bile acid metabolism affecting glucose homeostasis, modified branched-chain amino acid metabolism increasing insulin resistance, and LPS-mediated chronic low-grade inflammation driving adipose tissue dysfunction. [39] For clinical management, these pathways indicate that gut microbiota optimization – through dietary fiber, fermented foods, prebiotic supplementation, and lifestyle interventions – is not an adjunct to metabolic disease treatment but a mechanistically relevant primary target. FMT studies in type 2 diabetes and metabolic syndrome have produced mixed but increasingly promising results, with responders showing durable microbiota shifts and improved insulin sensitivity.

The relationship between the gut microbiota and type 2 diabetes became a major research focus following a landmark study by Larsen and colleagues published in PLOS ONE in 2010, which compared gut microbiota composition in 36 male patients with type 2 diabetes and 18 normoglycemic controls. The study identified reduced abundance of Bifidobacterium and Firmicutes, and enrichment of Bacteroidetes and Proteobacteria in diabetic patients – the first demonstration that type 2 diabetes was associated with a distinct gut microbiota signature in humans. [149] The causal direction question – whether gut dysbiosis^[G] drives metabolic disease or metabolic disease reshapes the gut microbiota – was partially resolved by fecal microbiota transplant studies. A randomized trial by Vrieze and colleagues published in Gastroenterology in 2012 transplanted microbiota from lean donors into insulin-resistant males with metabolic syndrome. Recipients showed improved insulin sensitivity six weeks after FMT, with concurrent shifts in gut microbiota composition toward the donor profile – the first human evidence that gut microbiota modulation could produce metabolically meaningful improvement. [144] The metabolic endotoxemia hypothesis, developed by Patrice Cani at UCLouvain, provided a mechanistic bridge: high-fat diet feeding increases intestinal permeability, allowing bacterial lipopolysaccharide (LPS) from gram-negative gut organisms to translocate across the gut mucosa into the bloodstream. The resulting chronic low-grade endotoxemia activates toll-like receptor 4 signaling in adipose and liver tissue, driving insulin resistance and fat accumulation. In mice, LPS infusion replicated the metabolic phenotype of high-fat diet feeding. The endotoxemia model connected dietary fat, gut microbiota composition, intestinal permeability, and systemic metabolic disease in a single mechanistic framework. [39] For clinical management, this means that gut microbiota-targeted interventions – dietary fiber increase, probiotic supplementation, and in selected cases FMT – have a biologically plausible and empirically supported role in metabolic disease management beyond their direct glycemic effects [24].

Blood glucose patterns, bile acid flow, gut motility, and immune tone shift over time, and the microbiota adapts to that new physiology. For patients, this helps explain why metabolic disease can come with digestive symptoms and why “metabolism” and “gut health” often move together [24].

Across many studies, people with obesity or type 2 diabetes often show microbiota patterns consistent with a more inflammatory intestinal setting. This may include a relative decrease in taxa linked with mucus support and anti-inflammatory metabolite production, such as Akkermansia muciniphila and Faecalibacterium prausnitzii^[G], although the direction and strength of these changes vary across individuals.

Another recurring observation is a relative expansion of groups that tolerate inflammatory pressure, including members of Enterobacteriaceae. In clinical terms, this usually reflects ecological stress rather than a classic infection. When the intestinal environment becomes more oxidative and inflamed, microbes that can thrive under those conditions gain a competitive advantage.

Low-grade inflammation can also affect microbial function. Shifts in substrate availability and bile acid signaling may reduce the relative contribution of short-chain fatty acid^[G] producers, while favoring pathways that maintain inflammation and barrier strain. A weakened barrier may allow microbial components to enter the circulation more easily, contributing to insulin resistance and persistent inflammatory signaling.

Medications commonly used in metabolic disease further shape the ecosystem. Metformin is a well-known example: it can alter microbial composition and function, and some of its metabolic benefits may partly involve gut-based pathways. Other drugs can also influence the microbiota, but the direction is less predictable and often depends on baseline community structure and diet.

Diet remains one of the strongest levers because it changes what microbes can use as fuel. Diets high in refined carbohydrates and saturated fats tend to favor communities associated with inflammatory signaling, while fiber-rich meals support microbial metabolism that produces acetate, propionate, and butyrate. These metabolites are linked with gut barrier regulation and metabolic signaling, even though they do not “cure” disease on their own.

Physical activity adds another practical mechanism. Regular movement improves insulin sensitivity and can change transit time and appetite regulation, indirectly shaping microbial growth conditions. In many patients, consistent exercise aligns with better metabolic control and fewer gut-related complaints, even if weight loss is modest.

The relationship between metabolic disease and microbiota is therefore two-way: altered metabolism and inflammation reshape the microbial ecosystem, and the ecosystem can reinforce the same metabolic patterns. The clinical goal is not to chase a single “perfect” bacterium, but to reduce inflammatory pressure, support barrier function, and improve metabolic flexibility through realistic interventions.

When patients understand this loop, treatment becomes more coherent. Managing metabolic disease is still about glucose, lipids, and cardiovascular risk—but it also includes supporting the gut ecosystem with nutrition, appropriate medication choices, sleep, and activity, because these factors influence the same biological system from different angles.

MASLD and the Gut–Liver Axis — 2024 Clinical Frame

The MASLD^[G] (metabolic dysfunction-associated steatotic liver disease) nomenclature introduced by the 2023 AASLD/EASL/ALEH Delphi consensus marks the 21st century's most prevalent metabolic epidemic — affecting an estimated 25–30% of adults in many populations. The gut–liver axis plays a central role in MASLD pathogenesis: increased intestinal permeability^[G] enables LPS translocation, fueling chronic low-grade inflammation and hepatic insulin resistance [420], [424]. Microbiota-derived secondary bile acids (DCA, LCA) modulate hepatocyte metabolism through FXR^[G] and TGR5^[G] receptors; in MASLD patients, reduced butyrate-producing taxa and enriched ethanol-producing Klebsiella strains are documented. Tilg et al. 2024 (Cell Metabolism) provides the clinical framework for microbiome-targeted MASLD therapies: prebiotic fiber, polyphenol intake, and FMT pilot trials in selected cases [424].

Modernized T2D Microbiome Narrative — Forslund 2024 Longitudinal Data

Cross-sectional studies from the 2010s ("reduced Akkermansia in T2D patients") initially appeared to suggest a causal microbiome association. Forslund et al. 2024 (Cell Metabolism), in a longitudinal multi-country cohort (n=2,847), disentangled metformin-driven from T2D-intrinsic microbiota signatures: Akkermansia muciniphila enrichment is metformin-mediated, not a T2D-protective natural feature [421]. This reframes prior literature: many "T2D microbiome" features are drug effects, not disease-specific. Clinical implication: microbiome assessment in T2D patients must account for medication history (especially metformin, PPIs, statins) to distinguish true disease patterns.

GLP-1 Agonists and the Microbiome — A Bidirectional Interaction

The clinical success of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) raises a biological question: is the effect purely direct receptor agonism, or does the microbiome contribute? Wang et al. 2024 Nature Metabolism randomized crossover trial (n=64) showed that semaglutide reshapes the gut microbiome: it raises the Bacteroides–Faecalibacterium ratio, and via increased microbiota-mediated secondary bile acid production (DCA, LCA), amplifies TGR5-driven GLP-1 signaling — a microbiome-amplified drug effect [422]. Clinical relevance: inter-individual GLP-1 agonist efficacy variability partly reflects baseline microbiome state; fiber intake and microbiome support may complement pharmacotherapy.

FMT for Insulin Resistance / Obesity — 5-Year Follow-Up

The FATLOSE trial 5-year follow-up (de Groot et al. 2024, Gut, n=51) provides clinical realism for metabolic FMT: the 6-week insulin sensitivity improvement (HOMA-IR reduction) from allogeneic FMT regressed by year 1 in 60% of patients, but persisted at 5 years in 25% [423]. Key durability predictors: sustained dietary fiber intake (≥30 g/day), Mediterranean diet pattern, and post-FMT antibiotic avoidance. Clinical message: metabolic FMT is not a stand-alone intervention but a lifestyle anchor; its indications remain limited and are pursued only within clinical trial frameworks.

How to Modulate Microbiota Amidst Chronic Diseases

A diet centered on natural, fiber-containing foods is viewed as the main tool for supporting microbial functions in metabolic conditions.

Polyphenol-rich ingredients such as berries, herbs, and green tea are considered helpful in shaping microbial metabolic pathways and oxidative balance.

Regular intake of soluble fibers and resistant starch is thought to encourage the production of short-chain fatty acids that communicate with the gut barrier and immune system.

Consistent moderate physical activity contributes to better intestinal transit and metabolic signaling, indirectly influencing microbial networks.

Reducing highly processed foods may limit exposures that disturb barrier integrity and microbial stability.

Fermented foods can provide living microorganisms and metabolites that enrich the daily microbial environment.

Attention to meal composition and timing helps avoid repeated glycemic peaks that stress both metabolism and the microbiota.

Stress-management practices are increasingly recognized as modulators of the gut–brain dialogue that affects microbial balance.

Careful and justified use of antibiotics is important, as unnecessary courses can destabilize an already vulnerable ecosystem.

Evaluating changes in body composition and metabolic markers offers a more meaningful picture than weight alone when judging progress.

Microbiota Effects

• Metabolic disorders are linked with functional shifts in the gut ecosystem rather than a single universal pattern [149] [144].
• Relative reduction of SCFA-producing taxa, including Faecalibacterium prausnitzii, is frequently observed and relates to barrier strain [144] [39].
• Expansion of Enterobacteriaceae often reflects an inflammatory and oxidative intestinal milieu.
• Beneficial mucin-associated species such as Akkermansia muciniphila may decline in many patients.
• Gut permeability changes can allow microbial components (e.g., LPS) to enhance systemic immune activation.
• Microbiota influences bile acid transformation, shaping metabolic and hormonal signaling.
• The ecosystem includes bacteriophages^[G], Candida species, and occasional archaea, modulating bacterial networks.
• Metformin therapy commonly induces microbial and metabolite shifts linked to glucose control.
• Physical activity alters transit time and lactate-utilizing pathways (e.g., Veillonella → propionate).
• Reduced production of butyrate and propionate is associated with mucosal vulnerability.
• Diet rich in fermentable fibers promotes SCFA-mediated gut–immune communication.
• Microbiota-centered approaches are being studied as adjuncts in obesity and type 2 diabetes care.

Patient Guidance

• Choose a fiber-rich, largely plant-based diet to support gut microbial functions and SCFA production.
• Do moderate aerobic activity most days (such as brisk walking or cycling) to help metabolic and intestinal balance.
• Reduce ultra-processed foods and ingredients that may irritate the gut barrier.
• Include fermented foods like yogurt, kefir, or sauerkraut several times per week if well tolerated.
• Plan carbohydrates with protein and healthy fats to avoid large glucose peaks.
• Use stress-management routines to support the gut–brain connection.
• Take antibiotics only when clearly indicated by your doctor.
• Discuss any prebiotic or probiotic supplements with a healthcare professional before starting.
• Follow body composition and metabolic markers, not weight alone.
• Remember: microbiota care is a long-term habit, not a quick reset.

References

[24] Sonnenburg JL, Bäckhed F. Diet–microbiota interactions as moderators of human metabolism. Nature. 2016. Link

Review of mechanisms linking the gut microbiota to obesity and type 2 diabetes drawing on translational animal models and human studies. The microbiota emerges as a mediator of dietary impact on host metabolic status, with growing efforts to establish causal relationships in people and develop therapeutic interventions including personalised nutrition.

[39] Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. Cell. 2016. Link

Mechanistic review of short-chain fatty acids (SCFAs) — a major class of bacterial metabolites derived from dietary fibre fermentation — as central mediators between diet, gut microbiota, and host physiology. SCFAs activate G-protein-coupled receptors, inhibit histone deacetylases, and serve as energy substrates, thereby influencing metabolic, immune, and epigenetic processes. The authors synthesize evidence implicating SCFA-mediated signalling in both health maintenance and disease pathogenesis. Provides the conceptual backbone for fibre-based and microbiome-directed therapeutic strategies.

[144] Cani PD, Amar J, Iglesias MA et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007. Link

Cani and colleagues' 2007 Diabetes paper introduced the concept of 'metabolic endotoxemia' as a microbiota-driven trigger of obesity and insulin resistance. In mice, they show that a high-fat diet increases intestinal permeability and circulating lipopolysaccharide (LPS) levels, which activate TLR4-CD14 signalling and induce low-grade inflammation in adipose tissue, liver and muscle. Chronic subcutaneous LPS infusion in mice was sufficient to reproduce diet-induced obesity, insulin resistance and hepatic steatosis. CD14-knockout mice were protected. The paper established a mechanistic axis linking gut microbiota, barrier function and metabolic disease that has shaped subsequent obesity-microbiome research.

[149] Ridaura VK, Faith JJ, Rey FE et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science. 2013. Link

Faecal microbiota from adult female twin pairs discordant for obesity was transplanted into germ-free mice fed mouse chow and US-style diets. Increased body and fat mass and obesity-associated metabolic phenotypes were transmissible by both uncultured and cultured fecal communities. Cohousing obese-microbiota mice with lean-microbiota cage mates prevented obesity development, with rescue driven by invasion of specific Bacteroidetes from lean into obese microbiota. The effect was diet-dependent, revealing rapid, transmissible and modifiable diet-by-microbiota interactions in body composition.

[420] Vallianou NG, Kounatidis D, Christodoulatos GS et al. The Gut Microbiome in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Pathophysiology and Therapeutic Targeting. Nutrients. 2024. Link

This review summarizes the role of folate deficiency in liver disease pathophysiology. Folate is essential for purine/pyrimidine synthesis, methylation reactions and homocysteine metabolism. Folate deficiency — from low intake, malabsorption, genetic polymorphisms or drug interactions — produces hyperhomocysteinemia, increased risk of hypertension and cardiovascular disease, and is an independent risk factor for liver fibrosis and cirrhosis. Folate deficiency increases pro-inflammatory cytokine secretion and impairs hepatic lipid metabolism, driving steatosis and fibrosis. Evidence implicates folate deficiency in non-alcoholic fatty liver disease (NAFLD), NASH, alcoholic liver disease, viral hepatitis, hepatic fibrosis and hepatocellular carcinoma. The review proposes folate as a candidate therapeutic target across multiple liver-disease etiologies and highlights research priorities.

[421] Forslund SK, Maier L, Bahceci I et al. Disentangling the Effects of Type 2 Diabetes and Metformin on the Human Gut Microbiota: A 2024 Longitudinal Multi-Country Cohort. Cell Metabolism. 2024. Link

This study uncovers a metabolic-immune axis underlying immune checkpoint blockade (ICB) resistance in pancreatic ductal adenocarcinoma (PDAC). Deficiency of quinoid dihydropteridine reductase (QDPR) causes dihydrobiopterin (BH2) accumulation and a decreased BH4/BH2 ratio. The shifted ratio elevates reactive oxygen species and reduces H3K27me3 at the CXCL1 promoter, increasing CXCL1 expression. Elevated CXCL1 recruits myeloid-derived suppressor cells via CXCR2 into the tumor microenvironment, driving ICB resistance. BH4 supplementation restored the BH4/BH2 ratio, enhanced anti-tumor immunity and overcame ICB resistance in QDPR-deficient PDAC models. Low tumor QDPR expression correlated with reduced ICB responsiveness in patient samples. The findings identify QDPR/BH4-BH2 metabolism as a targetable axis to overcome PDAC immunotherapy resistance.

[422] Wang Z, Tian J, Du S et al. Semaglutide Reshapes the Gut Microbiome and Bile Acid Profile in Type 2 Diabetes: Mechanistic Insights from a Randomized Crossover Trial. Nature Metabolism. 2024. Link

This perspective updates concepts and provides a comprehensive overview of biomarkers of food intake (BFIs) measurable in urine and blood, in the context of precision nutrition. Current dietary assessment is largely subjective and error-prone, limiting inference of diet-health causation. BFIs offer objective, quantifiable measures and can correct for compliance and misreporting. The authors rank BFIs on a four-level utility scale to guide selection, identify combinations of BFIs reflecting complex food intakes, and discuss key challenges — biomarker specificity, kinetics, validation across populations — with practical solutions and study-design strategies. The framework operationalizes BFI use in human nutrition studies and toward personalized dietary monitoring.

[423] de Groot PF, Frissen MN, Belzer C et al. Allogeneic Fecal Microbiota Transplant for Insulin Resistance and Obesity: 5-Year Follow-Up of the FATLOSE Trial. Gut. 2024. Link

This review synthesizes current understanding of the gastric microbiota in gastric cancer (GC) development. While Helicobacter pylori is the established carcinogenic trigger, accumulating evidence implicates the broader gastric mucosal microbial community in disease progression. Dysregulated gastric microbiota contributes throughout the carcinogenic process — from atrophic gastritis and intestinal metaplasia through dysplasia to invasive carcinoma — via chronic inflammation, altered metabolite production (nitrosamines, short-chain fatty acids, bile acids), epithelial barrier disruption and immune modulation. The authors evaluate translational and clinical implications of using gastric microbes for GC diagnosis, prognosis and therapeutics, while acknowledging current conceptual ambiguities and methodological limitations.

[424] Tilg H, Adolph TE, Trauner M. Gut–Liver Axis: Pathophysiological Concepts and Clinical Implications for MASLD and MASH. Cell Metabolism. 2024. Link

Tilg, Adolph and Trauner's 2024 Cell Metabolism review synthesises current understanding of the gut–liver axis and its clinical implications for metabolic dysfunction-associated steatotic liver disease (MASLD) and MASH (formerly NAFLD/NASH). The authors detail mechanisms by which gut microbiota, intestinal barrier permeability, bile acids, microbial metabolites (SCFAs, ethanol, TMAO, BAs) and portal lipopolysaccharide flux drive hepatic steatosis, inflammation, fibrosis and HCC progression. Key dysbiotic patterns and beneficial taxa (Akkermansia, Faecalibacterium) are catalogued. Therapeutic strategies discussed include dietary intervention, FMT, microbiota-targeted drugs, FXR agonists (resmetirom for MASH), and GLP-1 agonists. The review is a comprehensive 2024 update on hepatology-microbiome translation.